<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, generally of the non-Hodgkin type (NHL), and with a preference to diffuse large cell B <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (DLCBL), in <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE), has been analysed in an exhaustive recent literature </plain></SENT>
<SENT sid="1" pm="."><plain>The combination of germline and <z:hpo ids='HP_0001428'>somatic mutations</z:hpo>, persistent immune overstimulation and the impairment of immune surveillance facilitated by immunosuppressive drugs, is thought to be at the origin of the increased <z:hpo ids='HP_0002665'>lymphoma</z:hpo> genesis </plain></SENT>
<SENT sid="2" pm="."><plain>However the treatment and course of such affected patients is less known, and prognosis is generally estimated as poor </plain></SENT>
<SENT sid="3" pm="."><plain>Out of 258 patients with complete/incomplete <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> and <z:e sem="disease" ids="C0409983" disease_type="Disease or Syndrome" abbrv="">secondary antiphospholipid syndrome</z:e> (APS) seen and treated at the institutional Day Hospital between 1982 and 2009, 6 developed <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (4 DLCBL, 1 Hodgkin's and 1 indolent lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="4" pm="."><plain>The first 5 patients were treated with high dose chemotherapy (HDCT) and achieved complete remissions (CR) with a follow-up comprised between 13 and 172 months </plain></SENT>
<SENT sid="5" pm="."><plain>One patient relapsed of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and died 15 months following CR, with persistent <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> serology </plain></SENT>
<SENT sid="6" pm="."><plain>One patient achieved complete remission (CR) of both diseases </plain></SENT>
<SENT sid="7" pm="."><plain>In the other 3 lupus serology, Antinuclear and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (ANA, aPL) persisted, with occasional <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> flares and vascular complications </plain></SENT>
<SENT sid="8" pm="."><plain>While eradication of the last <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cell is tantamount to cure in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic disease</z:e>, persistent autoantigenic overstimulation may contribute to the refractoriness of <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The implications of these results for the increasing utilisation of haematopoietic stem cell transplantation for severe <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> (SADS), with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> as a paradigm, are discussed </plain></SENT>
</text></document>